Episode 2 will cover the practical considerations for implementing HER2-targeted therapies in the treatment of HER2-positive NSCLC, including their integration into treatment pathways, patient selection, monitoring and managing toxicities, and the role of multidisciplinary collaboration.
If you do not have an existing account, you will be sent to the Springer Medicine log in page to start the video. You will only need to register once for full access to all content across all our programs.
Tune in to the audio version of this video on Spotify, Apple Podcasts, or your favorite podcast platform. Anytime, Anywhere!
Title: Experts in conversation: Practical considerations for implementation of HER2-targeted therapies
Release date: September 18, 2026
Expiration date: September 18, 2027
Estimated time to complete activity: 20 minutes
This program is intended for oncologists, pathologists, pulmonologists and oncology nurses, physician assistants, and those in the multidisciplinary teams worldwide who provide front-line care for patients with NSCLC.
Following completion of this independent educational program, you will be able to:
